Danish obesity drug maker Novo Nordisk's new CEO risks being on the losing side of a damaging price war as unprecedented price pressure forces it to slash the cost of its blockbuster Wegovy drug in...
Novo Nordisk risks weight-loss price war as discount pressures deepen
